Meeting abstracts Treatment options for metastatic urothelial bladder cancer (UBC) are limited. Mutational complexity is known to be high in UBC and may correlate with increased immunogenicity. MPDL3280A, a human PD-L1 monoclonal antibody containing an engineered Fc-domain designed to promote a Th1
No takes yet. Share an insight, caveat, or question.
Xiao et al. (2014) studied this question.